Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Maria J Alfonso Arvez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Mental Disorders, Hypoglycemic Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects. This study examined associations between GLP‐1RA use and initiation of a range of neuropsychiatric medications using real‐world prescription data. A Prescription Sequence Symmetry Analysis was conducted using Australia's Pharmaceutical Benefits Scheme 10% random sample between July 1, 2013 and December 31, 2024. Individuals with an incident dispensing of both a GLP‐1RA and a neuropsychiatric medication were included. Outcomes comprised antidepressants, medication for substance use disorder (SUD), antipsychotics, psychostimulants, antidementia medications, antiparkinsonian medications, antiepileptics, and antimigraine agents. Adjusted sequence ratios (aSRs) with 95% confidence intervals (CIs) were calculated using a one‐year exposure window, with sensitivity analyses varying various time windows. Among 2,033 individuals, semaglutide was the most common GLP‐1RA (50.6%), followed by exenatide (27.5%) and dulaglutide (21.9%). GLP‐1RA initiation was inversely associated with initiation of antidepressants (aSR: 0.85; 95% CI: 0.76–0.94) and medications for SUD (aSR: 0.70; 95% CI: 0.51–0.88). No significant associations were observed for other neuropsychiatric outcomes. GLP‐1RA use was inversely associated with subsequent initiation of antidepressants and medications for SUD, while no associations were identified for other neuropsychiatric marker medications. These findings highlight the need for further studies to clarify the nature and magnitude of these potential neuropsychiatric associations with GLP‐1RAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
- AK Clinical Research, Carlton, Victoria, Australia.
ORCID-Profile: Maria J Alfonso Arvez, Sam Wade, Darshna Goordeen, Jenni Ilomäki, Amanda J Cross, Monica Langiu, George S Q Tan
Zitieren
APA
Alfonso Arvez, M. J., Wade, S., Goordeen, D., Ilomäki, J., Cross, A. J., Langiu, M., & Tan, G. S. Q. (2026). Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70414
Vancouver
Alfonso Arvez MJ, Wade S, Goordeen D, Ilomäki J, Cross AJ, Langiu M, et al. Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70414
BibTeX
@article{AlfonsoArvez2026,
author = {Alfonso Arvez, Maria J and Wade, Sam and Goordeen, Darshna and Ilomäki, Jenni and Cross, Amanda J and Langiu, Monica and Tan, George S Q},
title = {Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70414}
}
EUVIMED